CHECKMATE-9LA compared Opdivo + low-dose Yervoy following two cycles of induction chemotherapy (i.e. patients never received I-O agents and chemo at the same time) to standard chemotherapy (up to four cycles) in first-line NSCLC regardless of PD-L1 expression. The trial met its OS primary endpoint at an interim analysis in Oct 2019 (#msg-151836584) and was a major comeback for BMY in first-line NSCLC after having botched the CHECKMATE-227 study.
The premise of CHECKMATE-9LA—using induction chemotherapy to arrest rapid disease progression and thereby procure more time for the dual I-O agents to work, without subjecting patients to the simultaneous toxicity of dual I-O agents and chemo—was borne out by the results.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.